{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 42,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Uses a case study (Osimertinib) to validate the proposed strategy for ALK/ROS1 targets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/10",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.33,
        "x": 0.63,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Significant 1L mPFS improvement & Movement up the treatment paradigm",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd2e95e6-467a-43a4-9c4b-8f38bf43a1bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Selective inhibition of the oncogenic driver + Overcoming treatment-emergent resistance mutations + Treating & preventing brain metastases + Avoiding treatment-limiting adverse events",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57c8f347-6fc4-4537-815d-47d415bd7b6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.84,
        "x": 0.08,
        "y": 0.46
      },
      "kind": "paragraph",
      "text": "Comparable resistance mutation rates after 1L TKI: ~50% ALK single mutation & ~40% ROS1 G2032R vs. ~50% EGFR T790M",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "923e4a5c-eab2-4be2-b23f-2e97866487bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "Sources: [1] Dagogo-Jack I. et al., Clin Cancer Res 2019; [2] Gainor J. et al. Cancer Discov. 2016; [4] Gainor J.F. et al., JCO Precision Oncol. 2017; [4] Ohashi K. et al., JCO 2013; [5] Osimertinib FDA package insert.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3edf0a3e-a5f1-44eb-b8cd-2ab5ea47f271",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.2,
        "y": 0.15
      },
      "kind": "title",
      "text": "Potential best-in-class ALK & ROS1 TKIs to overcome the combined medical needs of:",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bcd7638-df59-4c07-abc9-e83da19e5557",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.52,
        "x": 0.24,
        "y": 0.05
      },
      "kind": "title",
      "text": "Nuvalent ALK+ and ROS1+ NSCLC Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a0110a8-f65f-4c4f-98ac-e6b5a01fbf67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.06,
        "y": 0.54
      },
      "kind": "title",
      "text": "CASE STUDY Osimertinib for EGFR+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e07f8a23-de92-45e4-b0c8-0cdab2832460",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3672d250-8c98-42ae-95e3-d874910c5747",
      "evidence": "Potential best-in-class ALK & ROS1 TKIs to overcome the combined medical needs of: ... Avoiding treatment-limiting adverse events",
      "confidence": 0.8
    },
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "7b413a40-63a1-490b-a5f4-9a10b631bcbe",
      "evidence": "Significant 1L mPFS improvement & Movement up the treatment paradigm",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "case-study",
      "slug": null,
      "matchId": "270f4854-6a98-4c69-97ec-386b94879db2",
      "evidence": "Uses Osimertinib as a benchmark for the proposed strategy",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "a8e420e9-9c9e-4d1c-a1ef-2d1d5f7361f9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Nuvalent's approach as a potential best-in-class solution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}